<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/54F9413B-19F2-46DE-AFD4-245E4FB19B79"><gtr:id>54F9413B-19F2-46DE-AFD4-245E4FB19B79</gtr:id><gtr:name>Stellenbosch University</gtr:name><gtr:address><gtr:line1>Private Bag X1</gtr:line1><gtr:line2>19 Jonkershoek Road</gtr:line2><gtr:line3>Matieland</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54F9413B-19F2-46DE-AFD4-245E4FB19B79"><gtr:id>54F9413B-19F2-46DE-AFD4-245E4FB19B79</gtr:id><gtr:name>Stellenbosch University</gtr:name><gtr:address><gtr:line1>Private Bag X1</gtr:line1><gtr:line2>19 Jonkershoek Road</gtr:line2><gtr:line3>Matieland</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C11776E4-A150-4B15-9CDE-866FFD8E96DE"><gtr:id>C11776E4-A150-4B15-9CDE-866FFD8E96DE</gtr:id><gtr:firstName>Jayne</gtr:firstName><gtr:surname>Sutherland</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/224E3DE5-2D34-44B1-85D6-F106532CBF36"><gtr:id>224E3DE5-2D34-44B1-85D6-F106532CBF36</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Ota</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190071468"><gtr:id>14FFEA3A-3789-4C1C-9C18-884261EB93F8</gtr:id><gtr:title>Understanding Immunity to Tuberculosis using the TB case-contact research platform (TBCC)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190071468</gtr:grantReference><gtr:abstractText>Tuberculosis (TB) is a global health problem, particularly in developing countries due to over-crowded living conditions and high HIV infection rates. There has been no new vaccine for over 90 years and the current vaccine does not work in adults. There are also no diagnostic tests that can be used in health clinics without facilities such as x-ray, power or water. Unfortunately, these are the clinics that see 60% of patients. 
One of the reasons we have not developed new tests and vaccines is because the bacterium that causes TB constantly changes its appearance so it cannot be easily detected by the cells in the body trying to fight it. 
TB case-contact studies provide unique opportunities for the development of new tests and vaccines. When we diagnose someone with TB, we visit their home for two years to see if any of their family members (adults and children) also develop TB. We assume that if someone sleeps in the same room as the person with TB they are likely to get TB themselves (since TB is transmitted by coughing). If they don?t get TB, we can look at what types of cells are present in their blood that might have protected them. This will help us know what we should achieve with a new vaccine. We can also investigate the person with disease and see what their immune responses are like as this will help us to develop new diagnostic tests. 
Through our work we hope to develop better diagnostic tests and ultimately a vaccine that will contribute to eliminate TB world-wide.</gtr:abstractText><gtr:technicalSummary>Importance of the research:
Tuberculosis (TB) remains a daunting global health problem with over 9 million new cases and 1.4 million deaths each year. We urgently require new vaccines, diagnostics and treatment regimes but to achieve this we need a better understanding of the interaction between the underlying pathogen (Mycobacterium tuberculosis) and the host response to the pathogen. This can be determined using the spectrum of infection/disease states that are available to us through the TB case-contact (TBCC) platform. Our central research paradigm is that dynamic changes in host immune responses that take place during encounters with invading pathogens and during interventions such as treatment or vaccination, will allow us to reveal causal relationships with biomarkers. The MRC TB case-contact platform has been running since 2001 and has encompassed epidemiological, clinical, genetic, microbiological and immunological aspects of tuberculosis with over 80 peer-reviewed publications.

Aims of the TBCC:
Our aims are to analyse the host and pathogen at different stages of infection and disease that will inform on rational development of novel vaccines and diagnostics. 
 
Study design:
Following diagnosis of TB, patients are consented and recruited to the TBCC platform. Subsequently, field workers visit their household to recruit and consent family members (average 10 per household). Sputum samples from index cases are studied for bacterial load, drug-resistance, strain of infection and follow-up for treatment response. At the same time, blood and other body fluids are analysed for host immune responses to TB antigens. Household contacts are tested to determine presence of latent infection (90% of infected people remain asymptomatic throughout life) and are monitored for 2 years to determine any changes in infection/disease states. Blood samples from exposed but apparently uninfected household contacts are analysed to determine what factors contribute to protective immunity to TB. 

Clinical and diagnostic studies:
Our well established platform has allowed us to perform novel vaccine trials, multi-site biomarker studies; TB transmission studies; molecular typing of bacteria; implementation of new diagnostic tests such as the GeneXpert; host genetics and many more. The adult TBCC platform has also enabled the development of a pediatric TB program through Prof. Kampmann?s MRC Program Grant. Importantly, we have generated a unique and well-characterized bank of samples for future studies such as host genetics and ?omics research and also mycobacterial strains and transmission data.

Translational research and public health benefits:
Our major translational focus is on development of new diagnostic tests for adult and pediatric TB. We have 2 patents in this regard for development of point-of-care tests. All our research has a public health focus with potential to impact on policy and practice. Importantly, we have long-standing collaborations with leaders in the TB field: the Bill and Melinda Gates funded Grand Challenges project established us as a major player in multi-site consortiums, which are essential for development of next generation diagnostics and vaccines.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>9297115</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>New York University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mtb antigen diversity</gtr:description><gtr:id>27415FC5-C28A-42A5-85BE-C1A0A7C817B8</gtr:id><gtr:impact>2 publications and a presentation at Keystone TB meeting 2015</gtr:impact><gtr:outcomeId>HQ4Ms3veQEe-1</gtr:outcomeId><gtr:partnerContribution>In silico epitope prediction</gtr:partnerContribution><gtr:piContribution>Subject recruitment, all immunology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Immunology (LUMC-I)</gtr:department><gtr:description>TBVAC2020</gtr:description><gtr:id>0D5C364C-DE09-416B-8E3C-6D60FFB04514</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>58aef050375d81.11759674-1</gtr:outcomeId><gtr:partnerContribution>For LUMC: MLPA analysis of RNA from our study subjects
For MPIIB: Computational biology for metabolomics and RNA-seq data</gtr:partnerContribution><gtr:piContribution>For LUMC, this involved provision of RNA samples from TB-exposed household contacts. We will compare contacts who become infected to those that remain uninfected to determine early protective biomarkers. 

For MPIIB, this involved sending data generated from analysing RNA and plasma for bioinformatics</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stellenbosch</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Screen-TB</gtr:description><gtr:id>25C36C53-8FC4-431C-AE65-86B75BCB1820</gtr:id><gtr:impact>Recruitment of patients will not begin until mid-2016. Outputs will occur by 2019.</gtr:impact><gtr:outcomeId>5641e01be64f81.37068762-1</gtr:outcomeId><gtr:partnerContribution>Grant co-ordinator/PI</gtr:partnerContribution><gtr:piContribution>Dr. Sutherland is site-PI for a multi-site study on development of a rapid diagnostic test for TB. This involves recruitment of 200 patients with symptoms suggestive of TB but prior to diagnosis. These patients are then diagnosed for TB or other respiratory disorders (ORD) using GeneXpert and biomarkers for TB are determined. The second stage of the project will use 'real-time' finger-prick testing of patients at the outpatients clinic to validate our diagnostic test in a 'field' setting.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stellenbosch</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>AE-TBC</gtr:description><gtr:id>69C26D98-5821-4D3B-B4FA-B87F0EDA6FE3</gtr:id><gtr:impact>1 manuscript to date: Ota et al., ERJ, 2014. 
Multi-disciplinary: immunology, clinical, microbiology</gtr:impact><gtr:outcomeId>nHSVk6iLZvo-1</gtr:outcomeId><gtr:partnerContribution>Equal numbers of recruitment and analyses</gtr:partnerContribution><gtr:piContribution>This was a multi-site study (7 African field-sites, 2 European partners) for development of a rapid TB test. MRC Gambia recruited and analysed 200 subjects.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>GC6-2013</gtr:description><gtr:id>10EAF2C5-D0AF-419F-AA49-F86EAD1F2D38</gtr:id><gtr:impact>2 consortium papers (Sutherland et al., 2013, CMI; Sutherland et al., 2013, Plos One).
RNA-seq data published in Lancet in 2016. 
Multi-disciplinary: epidemiology, clinical, immunological, microbiological</gtr:impact><gtr:outcomeId>R2qTZJu48Cu-1</gtr:outcomeId><gtr:partnerContribution>Securing funding and providing resources for RNA and plasma analysis.</gtr:partnerContribution><gtr:piContribution>Part of multi-site study for TB biomarkers. MRC recruited patients and their household contacts to generate incident cases - contacts who develop active TB within 2 years of recruitment. These subjects hold the key to understanding protective immunity to TB. RNA, plasma and PBMC are being analysed for biomarkers of TB 'risk'.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Infection Biology</gtr:department><gtr:description>TBVAC2020</gtr:description><gtr:id>03F52525-0605-4327-A762-FFA3FCB3C23B</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>58aef050375d81.11759674-2</gtr:outcomeId><gtr:partnerContribution>For LUMC: MLPA analysis of RNA from our study subjects
For MPIIB: Computational biology for metabolomics and RNA-seq data</gtr:partnerContribution><gtr:piContribution>For LUMC, this involved provision of RNA samples from TB-exposed household contacts. We will compare contacts who become infected to those that remain uninfected to determine early protective biomarkers. 

For MPIIB, this involved sending data generated from analysing RNA and plasma for bioinformatics</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mask Study</gtr:description><gtr:id>CBD0A036-4644-4E49-A439-F9AAE3ECA578</gtr:id><gtr:impact>Publications pending. Multidisciplinary project including microbiology and immunology</gtr:impact><gtr:outcomeId>58aedfbcc15f99.18734987-1</gtr:outcomeId><gtr:partnerContribution>Provision of masks and analysis of all samples collected.</gtr:partnerContribution><gtr:piContribution>The Mask study involves analysis of TB transmission and thus use of our TB case-contact platform to correlate patient transmission with infection status of the contacts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>WHO Global task force</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58F7103D-1070-4334-85F6-EF61ED354B23</gtr:id><gtr:impact>Dr. Ifedayo Adetifa. WHO Global Task Force on TB Impact Measurement Multi-country global workshop on TB prevalence surveys TB surveillance Workshop in Accra, Ghana, April 2013

Discussion on TB prevalence surveys in Gambia and other countries. The prevalence of TB has been accurately measured in Gambia for the first time in 50 years through the Global Fund.</gtr:impact><gtr:outcomeId>LimfePjuo87</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7th EDCTP forum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C6C09CE-CD1B-4EE6-9B41-E3D951F8C2C9</gtr:id><gtr:impact>Talk generated discussion from researchers and networking opportunities

Talk prompted discusssion for future research directions in W. Africa</gtr:impact><gtr:outcomeId>54608bb57522d7.03117156</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TB2016 conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>781B8583-F896-4392-A615-9D58591D72F3</gtr:id><gtr:impact>TB2016 was adjunct to AIDS2016 and was the first time a TB meeting was attached to the internationally renowned AIDS consortium. The meeting included policy makers, activists, researchers and patients from around the globe. This resulted in increased awareness of TB which is directly related to the AIDS epidemic.</gtr:impact><gtr:outcomeId>58aee6ee9878f4.93818188</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immunology workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C161E40-0315-4603-8FB2-6CA6B061FC69</gtr:id><gtr:impact>70 post-graduate students and 15 international faculty attended an immunology workshop for West Africa. This was the first time such an event had been held in the region and consisted of lectures and practical sessions. The students also presented posters with prizes for the top 3. The event was deemed highly successful and generated mentoring and networking.</gtr:impact><gtr:outcomeId>58aeed68da1150.37746512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Networking</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>35CDF82A-39A0-4AF6-A1C8-A913E6C819BA</gtr:id><gtr:impact>The meeting was organised to build on our links with the National TB control program, which is vital for our on-going TB research in The Gambia.

Increased patient recruitment. Better communication link between MRC and the external health clinics. Better community engagement for our work at MRC. Better government interactions.</gtr:impact><gtr:outcomeId>j95rz2dyuLL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Tuberculosis day</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FAD3BA5C-56A2-4F48-AA75-47CF8599BDB5</gtr:id><gtr:impact>World Tuberculosis day is marked in the country. On this occassion a presentation was made detailing the increasing high prevalence of the disease and sensitising the community on how to detect it early for treatment. These data/talk was broadcast via the national radio and television to the entire public.

Community engagement and awareness of the TB problem, to facilitate increased health-seeking behaviours and inform the community and government of the work MRC conducts in regards to TB. This in turn facilitates continued collaboration between MRC and the National TB control program.</gtr:impact><gtr:outcomeId>mqoqTWp8bxd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World TB day 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6C7EC679-F51D-45E9-B383-F89E08FA1CCD</gtr:id><gtr:impact>Increased engagement with communities and strengthened ties with the national TB program

sustained collaborations with the national TB program</gtr:impact><gtr:outcomeId>545f72f633d3c5.64632787</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TB training workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7194B3F7-D345-458E-B83F-4507C15CB91F</gtr:id><gtr:impact>MRC is the principal site for microbiological training for sites involved in WANETAM. We provide training in culture, smear, GeneXpert and other techniques essential for TB diagnosis.

Increasing TB diagnosis and capacity building in developing countries. Reducing the burden of TB. Providing economic benefits to developing countries.</gtr:impact><gtr:outcomeId>RZ3PSw2jGoL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TB-sequel</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>337CE684-87DC-4AC6-ACC6-A61462C4C989</gtr:id><gtr:impact>Kick-off meeting for health systems networks which funds 5 projects in Africa for capacity building and development. The discussions generated new avenues for future funding and ideas for sustainability of the research networks.</gtr:impact><gtr:outcomeId>58aee7e44b15a6.62690630</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LAMP TB test</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Foundation for Innovative New Diagnostics (FIND)</gtr:fundingOrg><gtr:id>9F579D9B-31F4-47F4-A1C3-CFDEADFB083B</gtr:id><gtr:outcomeId>545f6fb73a4153.72628990</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DGF</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0AAE9C54-C6C2-401C-B059-930646A5B44A</gtr:id><gtr:outcomeId>58aed68a872024.58979357</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>480000</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>TBVAC2020</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Commission H2020</gtr:fundingOrg><gtr:id>8F2161CC-9F55-4AB5-B393-B4D1B5F35189</gtr:id><gtr:outcomeId>545f6f635e6d42.43262303</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Screen-TB</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>730ECA23-86BF-4323-8907-D5CB42219651</gtr:id><gtr:outcomeId>5641d4562a3113.99652962</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>BMBF</gtr:description><gtr:end>2021-06-02</gtr:end><gtr:fundingOrg>Government of Germany</gtr:fundingOrg><gtr:id>09F8ADA9-D1C7-459A-AF8A-336A5E978FC7</gtr:id><gtr:outcomeId>5641d40b593ff2.21663186</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC mid-career grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AED1D32E-BCC3-4E6B-8F96-6049B5DCDD65</gtr:id><gtr:outcomeId>545f7048276142.36113002</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital funds</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A707C54E-2663-4F93-BE12-9E90886DF5B5</gtr:id><gtr:outcomeId>545f6ffcf07280.92149424</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of sputum host biomarkers for diagnosis of TB. The biomarkers will be used for future development of a rapid TB test.</gtr:description><gtr:grantRef>MC_U190071468</gtr:grantRef><gtr:id>8392A75F-ED2E-4183-8156-9991D4B271D7</gtr:id><gtr:impact>None to date</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>U56YoHYB7QC</gtr:outcomeId><gtr:patentId>GB1316524.6 International-phase PCT application, publication WO15/040377</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Host biomarkers in Sputum for rapid TB diagnosis</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO guidelines on IGRA</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>B578CF73-6312-4281-BB52-A18AD926A26C</gtr:id><gtr:impact>Impact on policy - Gambia studies referenced in WHO guidelines on use of IGRAs in high vs low burden countries providing robust evidence of IGRAs limited performance in this setting compared to low burden non BCG vaccinated tourists. References also included in WHO commissioned review of IGRA performance in children.</gtr:impact><gtr:outcomeId>GCpCLorTj35</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We are seeking to develop a lateral flow test for detection of TB using biomarkers present in sputum (phlegm), which can be rolled out in basic healthcare clinics (level 3), without x-ray or other infrastructure. We are applying for DPFS funding through MRC to continue this development.</gtr:description><gtr:id>B307EAC0-9EBA-4259-BEB9-497E0F86B368</gtr:id><gtr:impact>Please note - these are expected impacts once the test is rolled out.</gtr:impact><gtr:outcomeId>TbGhLCMDboM</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Biomarkers in sputum for rapid TB diagnosis</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F9059305-628C-46E5-87E5-C11EC3C2AF18</gtr:id><gtr:title>Tuberculosis case-contact research in endemic tropical settings: design, conduct, and relevance to other infectious diseases.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>NKNiknESL9W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A239D704-731B-4936-A91F-CBD932E6556C</gtr:id><gtr:title>FOXP3 gene expression in a tuberculosis case contact study.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66a5780653887989616b1c6ad11d85bc"><gtr:id>66a5780653887989616b1c6ad11d85bc</gtr:id><gtr:otherNames>Burl S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_23588_18_17465993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9135E244-EAAC-4B24-8E4D-D23A262C936B</gtr:id><gtr:title>Thymic generation and regeneration.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c0f7600400e773058a7503cfff1387"><gtr:id>d7c0f7600400e773058a7503cfff1387</gtr:id><gtr:otherNames>Gill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_23588_18_12969308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4EE0471-8151-4CD0-8EDB-AF5379D2BF87</gtr:id><gtr:title>Sex-Differential Non-Vaccine-Specific Immunological Effects of Diphtheria-Tetanus-Pertussis and Measles Vaccination.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f0d00d6e320109e2364260747ad667c"><gtr:id>5f0d00d6e320109e2364260747ad667c</gtr:id><gtr:otherNames>Noho-Konteh F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58aee1c39bd962.18376940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA1438B4-0F2B-4C54-8560-C2063E92D14E</gtr:id><gtr:title>Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>P1WGHB2t6pj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8FB608D-3995-41CB-B030-8CE7E5210C54</gtr:id><gtr:title>Differential gene expression of activating Fc? receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>m1bfqvM6KEA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47E0D9DE-5149-4035-8352-5DAC2867004B</gtr:id><gtr:title>Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15841_21_22916192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>315E184F-A226-48C2-9415-2D199BF4B3E0</gtr:id><gtr:title>Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_23588_28_20435929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F071A117-514A-434D-A769-32BA3FCB6D52</gtr:id><gtr:title>Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9c8402918ea8e3bd47a06f8f7680221"><gtr:id>e9c8402918ea8e3bd47a06f8f7680221</gtr:id><gtr:otherNames>Wilson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_23588_28_23645847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>965E779B-066E-498A-9631-6A1B3D5C0C0F</gtr:id><gtr:title>Elevated serum 25-hydroxy (OH) vitamin D levels are associated with risk of TB progression in Gambian adults.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2438d434fe9a12d3adf0b3701db5a391"><gtr:id>2438d434fe9a12d3adf0b3701db5a391</gtr:id><gtr:otherNames>Owolabi O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>58aee16d29f205.87671256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF73EBB4-3CAD-4BA3-91B5-2357630B69F3</gtr:id><gtr:title>Clinical and radiological presentation of 340 adults with smear-positive tuberculosis in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/282ee537e59f47fc70f90b4c28b2844f"><gtr:id>282ee537e59f47fc70f90b4c28b2844f</gtr:id><gtr:otherNames>Rathman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_23588_18_14552563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>001B0154-9D4D-4330-A5BD-9847FD579A1E</gtr:id><gtr:title>Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>545f6c3dd91a26.95060321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0347949-E53B-43D6-9307-50BC8BF3E2B5</gtr:id><gtr:title>Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_24040170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E33D5D9-2EFE-4B8D-B4F6-B620AE390719</gtr:id><gtr:title>Interferon-? ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_23588_28_23220919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0372DC88-CE15-4A7B-84CB-5FB91B6FEC12</gtr:id><gtr:title>Surprisingly high specificity of the PPD skin test for M. tuberculosis infection from recent exposure in The Gambia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_18_17183699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69674CA5-A679-44DE-B241-10DE891449BA</gtr:id><gtr:title>Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f5a3cdc0204360c82d811780a0d893"><gtr:id>f8f5a3cdc0204360c82d811780a0d893</gtr:id><gtr:otherNames>Black GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn><gtr:outcomeId>pm_23588_18_19553548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94D87452-88C9-4128-B568-2E4DD6EDC715</gtr:id><gtr:title>IL-17 Production from T Helper 17, Mucosal-Associated Invariant T, and ?d Cells in Tuberculosis Infection and Disease.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3f7bbbedddc2abc66772e2cf6dc4233"><gtr:id>f3f7bbbedddc2abc66772e2cf6dc4233</gtr:id><gtr:otherNames>Coulter F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a901010bb4675.56760537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3B4ABFC-C482-4E46-AE8A-CA37754AECC8</gtr:id><gtr:title>Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>V2V6UKYxh4n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94154DF6-7917-4FF3-85A2-1C4D4A86725E</gtr:id><gtr:title>C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in The Gambia.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e0bc3277b90bda00da8287924ac5db"><gtr:id>30e0bc3277b90bda00da8287924ac5db</gtr:id><gtr:otherNames>Mendy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58aee1c4975241.48139003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EC055B5-F5C5-4729-B866-5749F74843B1</gtr:id><gtr:title>Digitised audio questionnaire for assessment of informed consent comprehension in a low-literacy African research population: development and psychometric evaluation.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd0b08c7569d3fbb892d3070c540098"><gtr:id>5bd0b08c7569d3fbb892d3070c540098</gtr:id><gtr:otherNames>Afolabi MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545f6c3e332314.54599590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49C3571D-A0C6-4140-9F66-E9ECAA153321</gtr:id><gtr:title>Human immune responses to vaccines in the first year of life: biological, socio-economic and ethical issues - a viewpoint.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15841_21_22728219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>559DF2FB-40B9-46E0-B9D9-515471F7E193</gtr:id><gtr:title>Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4343631aee7697faab563179dbe32c1"><gtr:id>a4343631aee7697faab563179dbe32c1</gtr:id><gtr:otherNames>Elliott TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5641c8b7195517.68893365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0680F8EF-3B04-490C-9EB0-62C818CE808A</gtr:id><gtr:title>The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>mBQTBo7Y78U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DFF13E9-36DE-4CF0-BB72-F47C65064F86</gtr:id><gtr:title>Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>545f6c3e853907.09017087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF615BF7-1822-4626-A59B-ED846D41D996</gtr:id><gtr:title>An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions: in regard to Lawton et al. (Int J Radiat Oncol Biol Phys 2007;69:646-655.).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/def8b430cbbd19a7cfed05f3a61eeb8e"><gtr:id>def8b430cbbd19a7cfed05f3a61eeb8e</gtr:id><gtr:otherNames>Millar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_23588_18_18406900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04329555-3945-43D8-8569-DE203766CB52</gtr:id><gtr:title>Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_23588_18_18281548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F06C3D8-3382-44D7-90E1-D565434E3208</gtr:id><gtr:title>Thymic regeneration: teaching an old immune system new tricks.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d42eb25a1d33fbd4c1d5c175f59d3ab6"><gtr:id>d42eb25a1d33fbd4c1d5c175f59d3ab6</gtr:id><gtr:otherNames>Berzins SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>pm_23588_18_12383769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A193121-CE9B-4C4E-81AB-1C4B62A15135</gtr:id><gtr:title>Broad adaptive immune responses to M. tuberculosis antigens precede TST conversion in tuberculosis exposed household contacts in a TB-endemic setting.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78ff61a1d89783ad0c374d1276061097"><gtr:id>78ff61a1d89783ad0c374d1276061097</gtr:id><gtr:otherNames>Buchwald UK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5641c8b6a554d4.37512646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD366F1C-71FF-4DE9-BE07-2C92B1D71AAE</gtr:id><gtr:title>The genome of Mycobacterium africanum West African 2 reveals a lineage-specific locus and genome erosion common to the M. tuberculosis complex.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed467b9b110c9f187ed7663f41ed5a07"><gtr:id>ed467b9b110c9f187ed7663f41ed5a07</gtr:id><gtr:otherNames>Bentley SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>pm_23588_28_22389744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A260CD-C4F4-4555-B8FD-6BD2E48EFF5E</gtr:id><gtr:title>Antibody and T-cell responses during acute and convalescent stages of invasive pneumococcal disease.</gtr:title><gtr:parentPublicationTitle>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1201-9712</gtr:issn><gtr:outcomeId>pm_23588_28_21330177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1E4E113-38FA-4BFF-ACD0-A9C999C55A99</gtr:id><gtr:title>Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733a867a8d7466c2a8a7078ad915e124"><gtr:id>733a867a8d7466c2a8a7078ad915e124</gtr:id><gtr:otherNames>Goldberg GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>pm_23588_18_16371932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>506F52F4-1A6F-4B01-B117-1CF2138E733F</gtr:id><gtr:title>Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/733a867a8d7466c2a8a7078ad915e124"><gtr:id>733a867a8d7466c2a8a7078ad915e124</gtr:id><gtr:otherNames>Goldberg GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_23588_18_17513799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8233EC42-5CD4-4C16-9A44-C8AA442373F4</gtr:id><gtr:title>Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bca9d82a686e42ee39f4ddff92513838"><gtr:id>bca9d82a686e42ee39f4ddff92513838</gtr:id><gtr:otherNames>Aiken AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>pm_23588_18_16573826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D139CAB-B74D-49ED-8602-D2848EF599B5</gtr:id><gtr:title>A blood RNA signature for tuberculosis disease risk: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f702a7e4ae9fb3946fa30a8cceb009e"><gtr:id>2f702a7e4ae9fb3946fa30a8cceb009e</gtr:id><gtr:otherNames>Zak DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58aee32da09f76.00591545</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CD56B70-9346-47F8-A2DF-F5750471A693</gtr:id><gtr:title>Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f803967a7704851d1409894efc16adb4"><gtr:id>f803967a7704851d1409894efc16adb4</gtr:id><gtr:otherNames>Finan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>tTfVFJJAwqH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67058171-BECC-4949-8561-D8EF47BD37A9</gtr:id><gtr:title>Infection with Helicobacter pylori is associated with protection against tuberculosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59d84c0588565e95bc1df2a0a04ae74a"><gtr:id>59d84c0588565e95bc1df2a0a04ae74a</gtr:id><gtr:otherNames>Perry S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_20098711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF3E6B64-20FA-48F1-91C0-6C267814F566</gtr:id><gtr:title>Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>pm_23588_18_17961228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECFF3B89-EEF5-4A2B-84BF-C89550FD0AB7</gtr:id><gtr:title>Spatial analysis of tuberculosis in an urban west African setting: is there evidence of clustering?</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/784fa7b3583a20b2a4b0063af15631de"><gtr:id>784fa7b3583a20b2a4b0063af15631de</gtr:id><gtr:otherNames>Touray K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>pm_23588_28_20406427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97392C87-0C91-4600-8355-45AD389FFB23</gtr:id><gtr:title>Complex anemia in tuberculosis: the need to consider causes and timing when designing interventions.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/109444a10d09e9ed58baf403ba7c3ac8"><gtr:id>109444a10d09e9ed58baf403ba7c3ac8</gtr:id><gtr:otherNames>Minchella PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5641c8b67705e6.36827993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63E0E97D-D7A5-48CA-AB0B-B2AB40734BCE</gtr:id><gtr:title>Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_23588_18_17564487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF4837A5-4F63-48FC-9521-FF07571CA749</gtr:id><gtr:title>Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_23588_18_16586366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9707C0F3-A4E6-43D2-BE63-6018AC902783</gtr:id><gtr:title>Antibody and T-cell responses during acute and convalescent stages of invasive pneumococcal disease.</gtr:title><gtr:parentPublicationTitle>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1201-9712</gtr:issn><gtr:outcomeId>jbNUmQ2XBUZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596A0100-6BAE-4503-A49F-BAF752571E09</gtr:id><gtr:title>Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2478fd36f580f88bf4f18d95bd685df3"><gtr:id>2478fd36f580f88bf4f18d95bd685df3</gtr:id><gtr:otherNames>Morris GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_21339808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D34EF54F-D2E8-44CF-BE44-CD046D6891BE</gtr:id><gtr:title>Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_18_18167540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF970AE1-DB1B-4093-BED6-B47299EBB0FB</gtr:id><gtr:title>Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>pm_23588_18_16651307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EC2CE4E-C06D-4385-A68B-94624A79A835</gtr:id><gtr:title>Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80e8b533eb8d95dfc5774b593f2b5244"><gtr:id>80e8b533eb8d95dfc5774b593f2b5244</gtr:id><gtr:otherNames>Joosten SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn><gtr:outcomeId>pm_23588_28_21956656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2811A05-264A-4432-B886-CB8C321D2F7D</gtr:id><gtr:title>Rising ELISPOT count prior to the onset of symptoms of full-blown tuberculosis disease.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_23588_18_17352104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2225944F-BA48-4933-B8D6-640F5DAA6848</gtr:id><gtr:title>Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_23588_18_15655747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A60BCBA-E018-4816-9E32-CDC8F62578EF</gtr:id><gtr:title>Mycobacterial T cell responses in HIV-infected patients with advanced immunosuppression.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f7dade8ac247a685e3a355d13ad829c"><gtr:id>9f7dade8ac247a685e3a355d13ad829c</gtr:id><gtr:otherNames>Hammond AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_23588_18_18194089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F15F40AA-3336-4E9E-9A72-A4ADCDEFB22C</gtr:id><gtr:title>Sequence diversity in the pe_pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognition.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa50494ebb1a33b6be4cdb6d7a4b83b5"><gtr:id>fa50494ebb1a33b6be4cdb6d7a4b83b5</gtr:id><gtr:otherNames>Copin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5641c9b4232987.18725322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80F89FE8-3E9D-40A7-BC4E-FE3A1121ECD7</gtr:id><gtr:title>Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/397a381e4e10507fd0c21480e1bb5371"><gtr:id>397a381e4e10507fd0c21480e1bb5371</gtr:id><gtr:otherNames>Ibanga HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>pm_23588_18_16870530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1A19549-6605-4E3A-8C1A-A61C8EEEC20D</gtr:id><gtr:title>Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ea9b9a2464d712e60c03cad0a454817"><gtr:id>8ea9b9a2464d712e60c03cad0a454817</gtr:id><gtr:otherNames>Chegou NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a9010f8304118.80193528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E9C9D30-D604-416A-A5A8-E802715F4D6C</gtr:id><gtr:title>Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5359b4cdf0ec290d7961f3168d2af07d"><gtr:id>5359b4cdf0ec290d7961f3168d2af07d</gtr:id><gtr:otherNames>Brookes RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_18_18698342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BEE84D6-CC5C-4DAE-9AEB-5B4D910F0938</gtr:id><gtr:title>Face mask sampling for the detection of Mycobacterium tuberculosis in expelled aerosols.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c06d92173eb1564a7391e886577f4cf"><gtr:id>4c06d92173eb1564a7391e886577f4cf</gtr:id><gtr:otherNames>Williams CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545f76a4e2ee65.77365753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4742B1A5-A6BF-44F5-98D1-61F1D572EB35</gtr:id><gtr:title>Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3327b507198c215ad56f639173d2269d"><gtr:id>3327b507198c215ad56f639173d2269d</gtr:id><gtr:otherNames>Hur YG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>545f6c3e0ab438.72155400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B78D96FF-3AA2-4D91-AE6C-9D148F677FA2</gtr:id><gtr:title>Bacterial Isolates and Antibiotic Sensitivity among Gambian Children with Severe Acute Malnutrition.</gtr:title><gtr:parentPublicationTitle>International journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b991a05bb435b0d9b82486d5bf925bc6"><gtr:id>b991a05bb435b0d9b82486d5bf925bc6</gtr:id><gtr:otherNames>Okomo UA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1687-9740</gtr:issn><gtr:outcomeId>qifRKyR37bt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0D45E98-68F2-4B0E-A043-B984DAF2E2A4</gtr:id><gtr:title>Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c13d5c3426d3d9cf62b9a40f941977f6"><gtr:id>c13d5c3426d3d9cf62b9a40f941977f6</gtr:id><gtr:otherNames>Bojang AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>56bda84a60f9a8.17742393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CCF1EF5-44E6-49DC-BBCC-F37CD0F8D22B</gtr:id><gtr:title>Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ea9b9a2464d712e60c03cad0a454817"><gtr:id>8ea9b9a2464d712e60c03cad0a454817</gtr:id><gtr:otherNames>Chegou NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58aee16cf237d2.71245581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6069A820-306E-4130-BF7D-9F2D625FD952</gtr:id><gtr:title>Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_18_17264885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD8B1DE6-AD0B-49B5-A3DA-EE88321A3F99</gtr:id><gtr:title>Differences between tuberculosis cases infected with Mycobacterium africanum, West African type 2, relative to Euro-American Mycobacterium tuberculosis: an update.</gtr:title><gtr:parentPublicationTitle>FEMS immunology and medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0928-8244</gtr:issn><gtr:outcomeId>pm_23588_28_20002176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A9214B9-8B30-4582-8308-C5914DC2DC7B</gtr:id><gtr:title>Effects of castration on thymocyte development in two different models of thymic involution.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/589dff78ccf1fa72f41b335e785cbba7"><gtr:id>589dff78ccf1fa72f41b335e785cbba7</gtr:id><gtr:otherNames>Heng TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_23588_18_16116185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F14BA91B-744B-46CF-9FAA-30F042F45599</gtr:id><gtr:title>Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_23588_18_19224636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A63B4434-787F-4EF5-8E88-6D6BBD8E8DF0</gtr:id><gtr:title>Use of spoligotyping and large sequence polymorphisms to study the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear-positive tuberculosis cases in The Gambia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>pm_23588_18_19193842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC93DE2E-C58E-4A1B-A684-90D85F2C4FA6</gtr:id><gtr:title>Alternative explanations for T-cell response to in-situ gene therapy for prostate cancer: in reply to Fujita et al. (Int J Radiat Oncol Biol Phys 2006;65:84-90).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe7081c6290ca9dc45fa61f9dd0e6eac"><gtr:id>fe7081c6290ca9dc45fa61f9dd0e6eac</gtr:id><gtr:otherNames>Millar JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_23588_18_17126227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28AFB0E2-8D18-45D2-B285-3B2E5EAD7F71</gtr:id><gtr:title>Contribution of Xpert&amp;reg; MTB/RIF to the diagnosis of pulmonary tuberculosis among TB-exposed children in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20cdfef2eadb068c553328286c9523b5"><gtr:id>20cdfef2eadb068c553328286c9523b5</gtr:id><gtr:otherNames>Togun TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5641c8b746af22.38189039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA31AE93-FE80-4FEF-9802-541A2971A143</gtr:id><gtr:title>Analysis of LAM and 38 kDa Antibody Levels for Diagnosis of TB in a Case-Control Study in West Africa</gtr:title><gtr:parentPublicationTitle>ISRN Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545e39189b54aa104dae1e0f2982a994"><gtr:id>545e39189b54aa104dae1e0f2982a994</gtr:id><gtr:otherNames>Gomez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>cFi7Mwgnu1w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C3D2314-ED9E-49F8-8A85-F8BFD2DBE77F</gtr:id><gtr:title>Comparative evaluation of BACTEC MGIT 960 with BACTEC 9000 MB and LJ for isolation of mycobacteria in The Gambia.</gtr:title><gtr:parentPublicationTitle>Journal of infection in developing countries</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7bff8f060e6adc0a1448df422adddbf"><gtr:id>a7bff8f060e6adc0a1448df422adddbf</gtr:id><gtr:otherNames>Otu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1972-2680</gtr:issn><gtr:outcomeId>pm_23588_18_19738351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34ABB34D-BD40-4041-9FCA-188DB771BD61</gtr:id><gtr:title>Delaying bacillus Calmette-Gu&amp;eacute;rin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66a5780653887989616b1c6ad11d85bc"><gtr:id>66a5780653887989616b1c6ad11d85bc</gtr:id><gtr:otherNames>Burl S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>aajPm2jebrR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832EF6FD-94BE-4B50-9260-43A4E5025B75</gtr:id><gtr:title>Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e45d4500cf0278521a4ff8036e4e3aa"><gtr:id>4e45d4500cf0278521a4ff8036e4e3aa</gtr:id><gtr:otherNames>Adegbola RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_23588_18_12729346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC813D9D-0305-4372-B301-D7592A798BC0</gtr:id><gtr:title>Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>WaJjm81aAYv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C727FAD1-D550-4D03-85B6-DA9BC9E775A1</gtr:id><gtr:title>Highly accurate diagnosis of pleural tuberculosis by immunological analysis of the pleural effusion.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_22295081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>104F85A1-5B34-487A-BF6D-A4468E91FA0A</gtr:id><gtr:title>Clinical presentation and outcome of tuberculosis patients infected by M. africanum versus M. tuberculosis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_23588_18_17394693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7CD64C2-3CE1-4C43-924E-6A66BBE0D25D</gtr:id><gtr:title>A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfade195e59376993f5bd5e519fb6b4c"><gtr:id>cfade195e59376993f5bd5e519fb6b4c</gtr:id><gtr:otherNames>Odutola AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15841_21_22749600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2868B6DC-7362-4675-9694-EF0A7FBDC1E2</gtr:id><gtr:title>Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>gtJZ6QePMVe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5114676-95C2-478F-83EF-B31D5B8A97BF</gtr:id><gtr:title>Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn><gtr:outcomeId>5641c862ada390.19482673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62AB29D8-E579-4672-A9C1-D1F03F4A66CF</gtr:id><gtr:title>Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>pm_23588_18_16784521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CF61513-7BDB-4654-AB10-2358423EBAFD</gtr:id><gtr:title>Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia.</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f71db002bb6bafc16ef2bd7481e49ac"><gtr:id>4f71db002bb6bafc16ef2bd7481e49ac</gtr:id><gtr:otherNames>Jackson-Sillah D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn><gtr:outcomeId>pm_23588_18_17368495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96DF2C85-A994-43A0-A0F4-BB0F3FA6DC4A</gtr:id><gtr:title>Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>58aee1c453dc29.93696433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9A40DF0-3DA2-4A18-B50C-05A32AF322A9</gtr:id><gtr:title>Evaluation of the contribution of major T cell subsets to IFN-gamma production in TB infection by ELISPOT.</gtr:title><gtr:parentPublicationTitle>Immunological investigations</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be0327eda774d7bba48096f2db083821"><gtr:id>be0327eda774d7bba48096f2db083821</gtr:id><gtr:otherNames>Lugos MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0882-0139</gtr:issn><gtr:outcomeId>pcgJVnU4fA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7743B7E8-845C-4659-A14E-5C7C1F91E462</gtr:id><gtr:title>Changes in Host Cytokine Patterns of TB Patients with Different Bacterial Loads Detected Using 16S rRNA Analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb9da33984e91d417cfb6e083548480c"><gtr:id>bb9da33984e91d417cfb6e083548480c</gtr:id><gtr:otherNames>Heslop R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58aee1c40a0d54.13509034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3716A8-294C-4037-B6FB-EBE25D6D78F5</gtr:id><gtr:title>Lessons in participant retention in the course of a randomized controlled clinical trial.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>545f6c3e5e8204.19759746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0882441E-B08E-4A73-978A-5E5458A8DF36</gtr:id><gtr:title>Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_23588_18_18702608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>382ADA1B-1078-4C48-B2B9-9C88BA7C66F2</gtr:id><gtr:title>DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c146bbb30bdb70831df4e66242ff3f9b"><gtr:id>c146bbb30bdb70831df4e66242ff3f9b</gtr:id><gtr:otherNames>Olesen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn><gtr:outcomeId>pm_23588_18_17611589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BC2DBDA-7C61-4398-BD78-29C12B8A04D2</gtr:id><gtr:title>Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d833ab54d3476fbbf4b134f1f61b22df"><gtr:id>d833ab54d3476fbbf4b134f1f61b22df</gtr:id><gtr:otherNames>Awoniyi DO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>58aee1c3d0ed31.28339815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4042E21D-32D9-4DBF-B5F9-7B24A5C3251B</gtr:id><gtr:title>Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24f3d440cc17a77c7ce7e4e2e08a95a8"><gtr:id>24f3d440cc17a77c7ce7e4e2e08a95a8</gtr:id><gtr:otherNames>Thye T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_23588_28_20694014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EFA5EF6-64F0-4898-B422-A180B894FA84</gtr:id><gtr:title>Iron homeostasis and progression to pulmonary tuberculosis disease among household contacts.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/109444a10d09e9ed58baf403ba7c3ac8"><gtr:id>109444a10d09e9ed58baf403ba7c3ac8</gtr:id><gtr:otherNames>Minchella PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>5641c8b6cdc804.28462618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7637DD0-473A-4D77-B674-792272168530</gtr:id><gtr:title>Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ec21bd2f573a922be2e247d9f4cff89"><gtr:id>7ec21bd2f573a922be2e247d9f4cff89</gtr:id><gtr:otherNames>Akinsola AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15841_21_22363544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E4F88C-33BB-4FE7-A68A-3B01ACB96EA2</gtr:id><gtr:title>Immunogenicity of antigens from the TbD1 region present in M. africanum and missing from &amp;quot;modern&amp;quot; M. tuberculosis: a cross- sectional study.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32e2c5e83ca8d1853991693161a6184d"><gtr:id>32e2c5e83ca8d1853991693161a6184d</gtr:id><gtr:otherNames>de Jong BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>MRMn7UYtPRc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FCC68C2-4D01-49A2-8763-8EF13C2F1291</gtr:id><gtr:title>Identification of probable early-onset biomarkers for tuberculosis disease progression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_21966464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A89BF97-3C2E-406D-B097-C4B2CD37CE0F</gtr:id><gtr:title>Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>58aee16d5d2a84.00726975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE7ADB35-D32A-4E83-B7DE-B61AC80B191A</gtr:id><gtr:title>Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_23588_18_15034828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6B81B3F-8EE7-4158-A97A-C1061251696D</gtr:id><gtr:title>The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>VUxnNA423eR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96CEEA51-78B0-45F8-A49E-8215D826C1BC</gtr:id><gtr:title>Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa.</gtr:title><gtr:parentPublicationTitle>Clinical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31280647f7f04f7868b4ebe948769d88"><gtr:id>31280647f7f04f7868b4ebe948769d88</gtr:id><gtr:otherNames>Corstjens PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9120</gtr:issn><gtr:outcomeId>5641c8b77253a8.67747336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A68EBADB-2734-4DEF-AD28-8EF57476C872</gtr:id><gtr:title>Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>545f6c3db36cb1.36056729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB6A44B7-B20B-4291-BF13-2B1672954230</gtr:id><gtr:title>MCP1 SNPs and pulmonary tuberculosis in cohorts from West Africa, the USA and Argentina: lack of association or epistasis with IL12B polymorphisms.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f33a6f489be7d124d660dda3fef518"><gtr:id>d7f33a6f489be7d124d660dda3fef518</gtr:id><gtr:otherNames>Velez Edwards DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23588_28_22384203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF624C18-CCEB-47D1-A8F8-4E3982C9B438</gtr:id><gtr:title>Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cce2128624262c905a1c0eca64edc701"><gtr:id>cce2128624262c905a1c0eca64edc701</gtr:id><gtr:otherNames>Jeffries DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_23588_18_16499260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1721E2CB-6EC6-4F3E-ABCC-9DD6C29D2FB5</gtr:id><gtr:title>The first phylogeographic population structure and analysis of transmission dynamics of M. africanum West African 1--combining molecular data from Benin, Nigeria and Sierra Leone.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2765a26bdd37caa8fbd71943ba6d74a8"><gtr:id>2765a26bdd37caa8fbd71943ba6d74a8</gtr:id><gtr:otherNames>Gehre F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545f6d794577c7.46542025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DF6D7AC-1C1A-44FF-AB6B-D3C33DA5CD91</gtr:id><gtr:title>High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>pm_23588_18_19683473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D95624D4-A99A-4924-9920-62F77EEB64D7</gtr:id><gtr:title>Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette-Gu&amp;eacute;rin Russia Vaccination.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8951bd2e3cc1e79b67eaed679998ac9"><gtr:id>a8951bd2e3cc1e79b67eaed679998ac9</gtr:id><gtr:otherNames>Darboe F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9010f876b6d2.63475709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BEE1F31-AB4D-48FD-97A3-E3B0083ACE6D</gtr:id><gtr:title>Immunogenic Mycobacterium africanum strains associated with ongoing transmission in The Gambia.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2765a26bdd37caa8fbd71943ba6d74a8"><gtr:id>2765a26bdd37caa8fbd71943ba6d74a8</gtr:id><gtr:otherNames>Gehre F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>pm_23588_28_24050158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A349EE5A-7212-46A3-97E0-31B17D1D2DB1</gtr:id><gtr:title>Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7428120f3ad7c1593e45ddd895029c3"><gtr:id>b7428120f3ad7c1593e45ddd895029c3</gtr:id><gtr:otherNames>Young JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>iNDqfMcJxb9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82D5BBF5-FFF6-42C7-9418-436ABEB8BFA1</gtr:id><gtr:title>Activation of thymic regeneration in mice and humans following androgen blockade.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_23588_18_16081852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D5DBF86-8A15-4700-B884-95E369BF576F</gtr:id><gtr:title>ESAT-6/CFP-10 fusion protein and peptides for optimal diagnosis of mycobacterium tuberculosis infection by ex vivo enzyme-linked immunospot assay in the Gambia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87cefccd249f1cbbc1484acf7fcec2ce"><gtr:id>87cefccd249f1cbbc1484acf7fcec2ce</gtr:id><gtr:otherNames>Hill PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>pm_23588_18_15872224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E719E7EE-DC9E-47E9-B6B0-4C828F0C3DD8</gtr:id><gtr:title>Health seeking behaviour, health system experience and tuberculosis case finding in Gambians with cough.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bed6ba8d33fde91c8d42d186813c6b"><gtr:id>c5bed6ba8d33fde91c8d42d186813c6b</gtr:id><gtr:otherNames>Kasse Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>pm_23588_18_16753057</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190071468</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>